Compound Monograph
Hesperetin
Hesperetin is the flavanone aglycone of hesperidin — the actually-absorbed, circulating active species behind citrus hesperidin. Its glucuronide metabolites are themselves bioactive; human efficacy data for the isolate are essentially absent, and most "hesperetin" clinical claims are really hesperidin or orange-juice trials.
Sources · 6
Where Does It Come From?
Hesperetin is a naturally occurring flavanone (aglycone), found in Yerba santa, Citrus peel and pith and 4 other sources. It is well tolerated orally (low toxicity).
Principal source Yerba Santa Eriodictyon californicum Herb monograph → 
Source Peppermint Mentha × piperita Herb monograph → Concentration
Content by Source
Concentrations not reported. No percent-dry-weight or mg/g figures have been published for this compound in its source plants.
Hesperetin at a Glance
Hesperetin is the flavanone aglycone of hesperidin — and the species that actually circulates, since hesperidin must have its sugar removed by gut bacteria before absorption.
An unusual feature of its pharmacology is that its glucuronide metabolites are themselves bioactive, which is not true of most flavonoid conjugates — those are usually treated as inactivation products.
Human efficacy data for the isolate are essentially absent; the clinical record belongs to hesperidin and citrus preparations.
What It's Used For
Hesperetin is the flavanone aglycone of hesperidin — and it is the species the body actually absorbs. Dietary hesperidin is a rutinoside that must first be de-sugared by colonic microbiota before hesperetin can enter circulation, which is why this molecule earns its own page: it owns the pharmacokinetics of the absorbed, active form. Two facts shape its evidence. First, there is essentially no monotherapy human efficacy trial of isolated hesperetin — the cardiovascular and metabolic human data usually attributed to it are really hesperidin or orange-juice trials, which live on the hesperidin page. Second, its circulating phase-II conjugates are not inert: hesperetin-7-O-glucuronide reproduces vascular and hypotensive activity 6Reference 6Hesperidin metabolite hesperetin-7-O-glucuronide, but not hesperetin-3’-O-glucuronide, exerts hypotensive, vasodilatory and anti-inflammatory activitiesView study →, so “circulating hesperetin” means bioactive conjugates. Its strongest signal is mechanistic — endothelial eNOS/nitric-oxide stimulation 5Reference 5Clinical trialCitrus polyphenol hesperidin stimulates production of nitric oxide in endothelial cells while improving endothelial function and reducing inflammatory markers in patients with metabolic syndromeView study → and Nrf2 antioxidant activation 10Reference 10Hesperetin ameliorates hepatic oxidative stress and inflammation via the PI3K/AKT–Nrf2–ARE pathwayView study →.
Support is an experimental score — weighted by study type (human > animal > in vitro) and volume. A beta, not a validated metric. Isolated-hesperetin efficacy evidence is thin, so scores stay low by design. Each application links to its write-up.
Hesperetin is the species behind citrus’s vascular signal. In endothelial cells the aglycone (not the glycoside) stimulates nitric-oxide production and Akt/eNOS activation 5Reference 5Clinical trialCitrus polyphenol hesperidin stimulates production of nitric oxide in endothelial cells while improving endothelial function and reducing inflammatory markers in patients with metabolic syndromeView study →, and the major circulating human metabolite hesperetin-7-O-glucuronide — but not the 3’-O-glucuronide — reproduces vasodilatory and hypotensive activity, showing the conjugate is itself active 6Reference 6Hesperidin metabolite hesperetin-7-O-glucuronide, but not hesperetin-3’-O-glucuronide, exerts hypotensive, vasodilatory and anti-inflammatory activitiesView study →.
Gap: the human clinical endpoints (flow-mediated dilation, blood pressure) were all tested as hesperidin or orange juice and live on hesperidin; there is no blood-pressure or hard-outcome RCT of isolated hesperetin 5,
The RESHES randomized trial reversed insulin resistance in overweight/obese subjects — but hesperetin was co-administered with trans-resveratrol, so the effect is not attributable to hesperetin alone 7Reference 7Reversal of insulin resistance in overweight and obese subjects by trans-resveratrol and hesperetin combination (RESHES trial)View study →. A systematic review of citrus flavanones on diabetes is suggestive but pools glycoside, aglycone and juice 8Reference 8Systematic reviewEffect of citrus flavanones on diabetes: a systematic reviewView study →; in vitro, hesperetin outperforms hesperidin on antidiabetic and antioxidant endpoints, consistent with the aglycone being the active form 9Reference 9In-vitro evaluation of the antidiabetic potential of hesperidin and its aglycone hesperetin under oxidative stressView study →.
Gap: no monotherapy human trial of hesperetin, and the glucose meta-analyses for the glycoside are null (see the hesperidin page) 7,
Robust and reproducible preclinically: hesperetin activates the PI3K/AKT–Nrf2–ARE axis to blunt hepatic oxidative stress and inflammation 10Reference 10Hesperetin ameliorates hepatic oxidative stress and inflammation via the PI3K/AKT–Nrf2–ARE pathwayView study →, inhibits NLRP3 inflammasome activation and pyroptosis in spinal-cord-injury models 11Reference 11Hesperetin ameliorates spinal-cord injury by inhibiting NLRP3 inflammasome activation and pyroptosisView study →, and engages Nrf2/ARE against isoproterenol-induced cardiac hypertrophy 12Reference 12Targeting the Nrf2/ARE signalling pathway to mitigate isoproterenol-induced cardiac hypertrophy: plausible role of hesperetinView study →.
Gap: entirely rodent/cell, at supraphysiologic free-aglycone concentrations well above the low, heavily-conjugated human plasma exposure; no human anti-inflammatory trial of the isolate 10,
A dedicated review compiles hesperetin’s neurodegeneration-relevant actions — antioxidant, anti-neuroinflammatory, and greater blood-brain-barrier permeability than the glycoside — across Alzheimer’s, Parkinson’s and ischemia models 13Reference 13Neuroprotective effects and therapeutic potential of the citrus flavonoid hesperetin in neurodegenerative diseasesView study →.
Gap: review and animal work only; no clinical neurological data, and human-relevant dosing is unestablished 13Reference 13Neuroprotective effects and therapeutic potential of the citrus flavonoid hesperetin in neurodegenerative diseasesView study →.
Cell studies and reviews describe cell-cycle arrest, apoptosis induction and, for example, Notch1-pathway activation driving differentiation and apoptosis in cancer lines 14,
Gap: in-vitro/animal, at high micromolar concentrations, with no in-vivo tumor-outcome or clinical evidence — a preclinical curiosity, not a therapeutic claim 14,
Hesperetin recurs as a hit in computational SARS-CoV-2 main-protease (Mpro/3CLpro) docking screens and flavonoid-antiviral reviews 16,
Gap: these are in-silico predictions and narrative reviews — there is no enzyme-assay-confirmed potency of isolated hesperetin and no clinical benefit; included only as a labeled computational signal 16,
Mechanisms
| Target / pathway | Effect | Relevant to |
|---|---|---|
| Endothelial Akt → eNOS / NO | ↑ endothelial nitric oxide, vasodilation (aglycone-driven, in vitro) | endothelial functionBP |
| Hesperetin-7-O-glucuronide (circulating conjugate) | regioselectively vasoactive/hypotensive — the metabolite is bioactive | vascular; PK–activity link |
| Nrf2 / ARE via PI3K–AKT | ↑ antioxidant/cytoprotective genes; ↓ oxidative stress | antioxidanthepato/cardio-protection |
| NLRP3 inflammasome / NF-κB | ↓ inflammasome activation, ↓ cytokines | anti-inflammatoryinjury models |
| Cell-cycle / apoptosis (incl. Notch1) | growth arrest, pro-apoptotic signaling | anticancer (preclinical) |
| CYP3A / P-glycoprotein inhibition | ↓ first-pass metabolism/efflux of co-substrates (rat/in-vitro) | drug-interaction plausibility |
Pharmacokinetics
This is the load-bearing section and the reason the aglycone deserves its own page. Hesperetin is the actually-absorbed and circulating species — dietary hesperidin only enters the body after its rutinose is stripped by colonic microbiota. Direct human pharmacokinetics of the aglycone exist: after single oral doses of the free aglycone, hesperetin appears in plasma with measurable Tmax/Cmax and is eliminated within about 24 hours 1Reference 1Clinical trialPharmacokinetics of the citrus flavanone aglycones hesperetin and naringenin after single oral administration in human subjectsView study →, and earlier work quantified plasma kinetics and urinary excretion after citrus intake 2Reference 2Plasma kinetics and urinary excretion of the flavanones naringenin and hesperetin in humans after ingestion of orange juice and grapefruit juiceView study →. Removing the sugar relocates and raises absorption — α-rhamnosidase-treated (deglycosylated) orange juice markedly increases and accelerates flavanone absorption versus native juice, direct human confirmation that the rhamnose cap is the bottleneck 3Reference 3Clinical trialAbsorption, conjugation and excretion of the flavanones naringenin and hesperetin from α-rhamnosidase-treated orange juice in human subjectsView study → (the controlled rutinoside-vs-glucoside comparison is detailed on the hesperidin page). Absorbed hesperetin is then almost entirely glucuronidated and sulfated, so free aglycone in plasma is minimal — but the conjugates are not inert (hesperetin-7-O-glucuronide is vasoactive 6Reference 6Hesperidin metabolite hesperetin-7-O-glucuronide, but not hesperetin-3’-O-glucuronide, exerts hypotensive, vasodilatory and anti-inflammatory activitiesView study →), and a flavanone-PK review contextualizes the low, saturable, formulation- and microbiome-dependent bioavailability 4Reference 4The pharmacokinetics of flavanonesView study →. A milligram figure without the form and matrix says little.
Clinical trials
There is essentially no monotherapy human efficacy trial of isolated hesperetin. The human record splits into pharmacokinetic studies that do use the aglycone or deglycosylated forms 1,
| Completed | Planned | Terminated | Preclinical |
|---|---|---|---|
| PK studies + 1 combination RCT | — | — | Extensive |
Last checked: July 2026.
Toxicity & Safety
Hesperetin is a dietary citrus flavanone with a long consumption history and low apparent toxicity. A regulatory-style program (mutagenicity, acute and subchronic toxicity) of a hesperetin-7-glucoside–β-cyclodextrin complex reported no genotoxicity and a favorable safety margin 19Reference 19Mutagenic, acute and subchronic toxicity studies of the hesperetin-7-glucoside–β-cyclodextrin inclusion complexView study →, and comprehensive reviews covering its toxicology, pharmacology and bioavailability find no signal of meaningful human toxicity at dietary or supplemental exposure 20,
On interactions, one point matters: the clinically important grapefruit–drug interaction is caused by furanocoumarins, not flavanones — hesperetin (a sweet-orange flavanone) does not inherit grapefruit’s warning. It does inhibit CYP3A and P-glycoprotein in rat and in-vitro models and raised felodipine exposure 18Reference 18In vitroEvaluation of first-pass CYP3A and P-glycoprotein activities using felodipine and hesperetin in Wistar rats and everted rat gut sacs in vitroView study → — biologically plausible but clinically unproven, and at free-aglycone concentrations rarely reached from dietary intake given first-pass conjugation. A reasonable, conservative caution applies to concentrated extracts taken with narrow-therapeutic-index CYP3A4/P-gp substrates, and alongside anticoagulant or antiplatelet therapy. Do not overstate.
Dosage
There is no established human dose of isolated hesperetin. Human pharmacokinetic studies used single oral doses of the free aglycone (study-specific, not therapeutic) 1Reference 1Clinical trialPharmacokinetics of the citrus flavanone aglycones hesperetin and naringenin after single oral administration in human subjectsView study →, and the one efficacy-adjacent human trial (RESHES) used hesperetin as part of a resveratrol-plus-hesperetin combination, so no clean hesperetin dose can be extracted 7Reference 7Reversal of insulin resistance in overweight and obese subjects by trans-resveratrol and hesperetin combination (RESHES trial)View study →. Delivered exposure depends on form (free aglycone or glucoside versus rutinoside) and heavy first-pass conjugation. Nothing here is a recommendation.
References
- Kanaze FI, Bounartzi MI, Georgarakis M, Niopas I (2007). Pharmacokinetics of the citrus flavanone aglycones hesperetin and naringenin after single oral administration in human subjects. European Journal of Clinical Nutrition. https://pubmed.ncbi.nlm.nih.gov/17047689/
- Erlund I, Meririnne E, Alfthan G, Aro A (2001). Plasma kinetics and urinary excretion of the flavanones naringenin and hesperetin in humans after ingestion of orange juice and grapefruit juice. The Journal of Nutrition. https://pubmed.ncbi.nlm.nih.gov/11160539/
- Bredsdorff L, Nielsen ILF, Rasmussen SE, et al. (2010). Absorption, conjugation and excretion of the flavanones naringenin and hesperetin from α-rhamnosidase-treated orange juice in human subjects. British Journal of Nutrition. https://pubmed.ncbi.nlm.nih.gov/20100371/
- Najmanová I, Vopršalová M, Saso L, Mladěnka P (2020). The pharmacokinetics of flavanones. Critical Reviews in Food Science and Nutrition. https://pubmed.ncbi.nlm.nih.gov/31650849/
- Rizza S, Muniyappa R, Iantorno M, et al. (2011). Citrus polyphenol hesperidin stimulates production of nitric oxide in endothelial cells while improving endothelial function and reducing inflammatory markers in patients with metabolic syndrome. The Journal of Clinical Endocrinology & Metabolism. https://pubmed.ncbi.nlm.nih.gov/21346065/
- Yamamoto M, Jokura H, Suzuki A, et al. (2013). Hesperidin metabolite hesperetin-7-O-glucuronide, but not hesperetin-3’-O-glucuronide, exerts hypotensive, vasodilatory and anti-inflammatory activities. Food & Function. https://pubmed.ncbi.nlm.nih.gov/23831969/
- Rabbani N, Xue M, Weickert MO, et al. (2021). Reversal of insulin resistance in overweight and obese subjects by trans-resveratrol and hesperetin combination (RESHES trial). Nutrients. https://pubmed.ncbi.nlm.nih.gov/34371884/
- Azhar S, Sabahat R, Sajjad R, et al. (2023). Effect of citrus flavanones on diabetes: a systematic review. Current Diabetes Reviews. https://pubmed.ncbi.nlm.nih.gov/35796456/
- Dhanya R, Jayamurthy P, et al. (2020). In-vitro evaluation of the antidiabetic potential of hesperidin and its aglycone hesperetin under oxidative stress. Cell Biochemistry and Function. https://pubmed.ncbi.nlm.nih.gov/31926116/
- Li J, Wang T, Liu P, et al. (2021). Hesperetin ameliorates hepatic oxidative stress and inflammation via the PI3K/AKT–Nrf2–ARE pathway. Food & Function. https://pubmed.ncbi.nlm.nih.gov/33977953/
- Liu Z, Tu K, Zou P, et al. (2023). Hesperetin ameliorates spinal-cord injury by inhibiting NLRP3 inflammasome activation and pyroptosis. International Immunopharmacology. https://pubmed.ncbi.nlm.nih.gov/37001385/
- Velusamy P, Mohan T, Ravi DB, et al. (2020). Targeting the Nrf2/ARE signalling pathway to mitigate isoproterenol-induced cardiac hypertrophy: plausible role of hesperetin. Oxidative Medicine and Cellular Longevity. https://pubmed.ncbi.nlm.nih.gov/32952852/
- Evans JA, Mendonca P, Soliman KFA, et al. (2022). Neuroprotective effects and therapeutic potential of the citrus flavonoid hesperetin in neurodegenerative diseases. Nutrients. https://pubmed.ncbi.nlm.nih.gov/35684025/
- Ferreira de Oliveira JMP, Santos C, Fernandes E (2020). Therapeutic potential of hesperidin and its aglycone hesperetin: cell-cycle regulation and apoptosis induction in cancer models. Phytomedicine. https://pubmed.ncbi.nlm.nih.gov/30975541/
- Patel PN, Yu XM, Jaskula-Sztul R, et al. (2014). Hesperetin activates the Notch1 signalling cascade, causes apoptosis and induces cellular differentiation in anaplastic thyroid cancer. Annals of Surgical Oncology. https://pubmed.ncbi.nlm.nih.gov/24419754/
- Narkhede RR, Pise AV, Cheke RS, et al. (2020). Recognition of natural products as potential inhibitors of COVID-19 main protease (Mpro): in-silico evidence. Natural Products and Bioprospecting. https://pubmed.ncbi.nlm.nih.gov/32557405/
- Russo M, Moccia S, Spagnuolo C, et al. (2020). Roles of flavonoids against coronavirus infection. Chemico-Biological Interactions. https://pubmed.ncbi.nlm.nih.gov/32735799/
- Sridhar V, Surya Sandeep M, Ravindra Babu P, Naveen Babu K (2014). Evaluation of first-pass CYP3A and P-glycoprotein activities using felodipine and hesperetin in Wistar rats and everted rat gut sacs in vitro. Phytotherapy Research. https://pubmed.ncbi.nlm.nih.gov/23881850/
- Moriwaki M, Kito K, Nakagawa R, et al. (2023). Mutagenic, acute and subchronic toxicity studies of the hesperetin-7-glucoside–β-cyclodextrin inclusion complex. International Journal of Toxicology. https://pubmed.ncbi.nlm.nih.gov/36280476/
- Akhter S, Arman MSI, Tayab MA, et al. (2024). Recent advances in the biosynthesis, bioavailability, toxicology, pharmacology and controlled release of hesperetin. Critical Reviews in Food Science and Nutrition. https://pubmed.ncbi.nlm.nih.gov/36416093/
- Song B, Hao M, Zhang S, et al. (2024). Comprehensive review of hesperetin: advancements in pharmacokinetics, pharmacological effects and novel formulations. Fitoterapia. https://pubmed.ncbi.nlm.nih.gov/39255908/
